Scilex Holding Company provided sales guidance for the fiscal year ended December 31, 2023. For the period, the company expects total product net sales were in the range of $46.5 million to $52.5 million, compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 22% to 38%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 USD | +3.67% | +25.56% | -44.61% |
May. 24 | Sector Update: Health Care Stocks Decline Late Friday Afternoon | MT |
May. 24 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.61% | 137M | |
+8.35% | 8.72B | |
-16.83% | 4.79B | |
+47.36% | 4.62B | |
+1.74% | 3.82B | |
+14.51% | 2.33B | |
-26.23% | 2.2B | |
+15.63% | 2.1B | |
-34.87% | 2.04B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SCLX Stock
- News Scilex Holding Company
- Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023